Justine Koenigsberg

Head of Investor Relations at Kymera Therapeutics (NASDAQ: KYMR)

[CNBC's Fast Money @CNBCFastMoney]

$KYMR shares notching a record close after giving a better-than-expected timeline for its fast-tracked ezcema oral treatment trial.

@KymeraTx CEO on record stock run, upbeat eczema oral treatment trial data

https://t.co/ENc6LiRnco

[Kymera Therapeutics @KymeraTx]

Thank you @BioCentury and @SelinaMKoch for featuring our Founder & CEO, @NelloMainolfi, on the #BioCenturyShow.

In this episode, Nello discusses the science and strategy of #TargetedProteinDegradation—its unique catalytic mechanism, ability to reach historically undrugged targets, and the challenges and opportunities that come with translating a new modality into meaningful therapies. He also highlights Kymera’s industry-leading work in immunology, where oral degraders like KT-621, our STAT6 degrader, can unlock new possibilities for millions of patients.

Listen to the full episode here: https://t.co/6nF7e7xils
#RevolutionizingImmunology

[Kymera Therapeutics @KymeraTx]

Our team is heading to Paris this week for the #EADVCongress! We’re excited to connect with fellow innovators in the #dermatology community and share presentations on our groundbreaking work to advance novel oral degrader medicines. Hope to see you there! #RevolutionizingImmunology

[Justine Koenigsberg @jkoenigsberg]

An unforgettable moment ringing the @NasdaqExchange opening bell with this incredible team! #RevolutionizingImmunology #NasdaqListed

[Kymera Therapeutics @KymeraTx]

What’s it really like to ring the @NasdaqExchange opening bell?

For Kymera, it started with a 4am bus ride from Watertown to Times Square—fueled by espresso, excitement, and an amazing crew of colleagues who made every moment unforgettable.

From early morning trivia and raffles on the bus to the thrill of stepping into the Nasdaq production studio, this milestone was more than a ceremony—it was a celebration of the groundbreaking science and incredible people who power our journey every day.

Check out some behind-the-scenes snapshots from our big morning in NYC, and the cheers back home as our team gathered to livestream the moment together. Thank you to everyone who helped make the day so memorable!
$KYMR #NasdaqListed #RevolutionizingImmunology

[BiotechTV @BiotechTV]

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: @KymeraTx Founder & CEO @NelloMainolfi discusses the safety, degradation, and biomarker profile he sees in the company's STAT6 healthy volunteer data. $KYMR

Full video: https://t.co/YWpddAMOJG

[Kymera Therapeutics @KymeraTx]

Hear from Juliet Williams, our Head of Research, in her new blog on how Kymera is expanding possibilities in #immunology by tackling coveted undrugged targets like #STAT6 with oral degrader medicines: https://t.co/qI5N3JKr7e
#RevolutionizingImmunology #TPD #PatientImpact

[Kymera Therapeutics @KymeraTx]

We recently celebrated our annual #Culture Week to recognize our team’s dedication to scientific excellence, genuine camaraderie, and commitment to improving patients’ lives – check out the festivities below! And we invite like-minded innovators to join us on our extraordinary journey to #RevolutionizeImmunology: https://t.co/DcSdUqJEmp
#Pioneer #Collaborate #Belong #Hiring #Biotech

[Kymera Therapeutics @KymeraTx]

“I was inspired to join this mission, leveraging my understanding of the patient experience in #immunology to contribute to breakthroughs that redefine what’s possible in this therapeutic area.” Hear more about how the Kymera team has opened new possibilities by targeting #STAT6 for #PatientImpact
https://t.co/K6vaCW3EEZ

[Kymera Therapeutics @KymeraTx]

The status-quo for immunology drugs is about to change. Learn more in our latest blog by Arsalan Shabbir, VP of Clinical Development, about how targeting #STAT6 is just the beginning in: “A Revolution in Immunology: Creating New Possibilities with Oral Medicines” https://t.co/K6vaCW3EEZ
#RevolutionizingImmunology #PatientImpact

[Kymera Therapeutics @KymeraTx]

2024 has been a year of #innovation and #excellence. We’ve made incredible progress advancing our industry leading #immunology portfolio of next generation oral drugs with potentially first-in-class profiles. We’re energized by the opportunity we have before us as we continue on the path to revolutionize treatment paradigms for patients – join our team in 2025! https://t.co/uOwjx5wxVq
$KYMR #Hiring #LifeSciences #DrugDiscovery #DrugDevelopment

[Kymera Therapeutics @KymeraTx]

We're honored to be recognized and featured as a #TopPlacetoWork in Massachusetts by the @BostonGlobe for a third consecutive year! This recognition is a testament to our team’s dedication to scientific excellence, genuine camaraderie, and commitment to improving lives. And we welcome like-minded pioneers to join us on our extraordinary journey to #RevolutionizeImmunology for millions of patients around the world: https://t.co/zP75IAR4R7
#workboston #Pioneer #Collaborate #Belong #Hiring #HiringNow

[Kymera Therapeutics @KymeraTx]

#ICYMI Check out our CEO @NelloMainolfi's recent blog on the ground breaking work done by the Kymera team to advance KT-621, our oral #STAT6 degrader with the potential to be a paradigm shifting medicine and change how #Th2 immuno-inflammatory diseases can be treated: https://t.co/vCtMn5cwfp
#RevolutionizingImmunology

[Kymera Therapeutics @KymeraTx]

We have been barrier breakers in our quest to target #STAT6. KT-621, our STAT6 degrader, has the potential to provide biologics-like activity with an oral small molecule profile for numerous #Th2 driven immuno-inflammatory diseases, and we’re thrilled to be the first company to advance a program like this into the clinic. Hear from our CEO @NelloMainolfi as he discusses the origin and opportunity of this milestone moment and what it means for patients!
#RevolutionizingImmunology
https://t.co/vCtMn5cwfp

[Kymera Therapeutics @KymeraTx]

Thank you @bradloncar for featuring our CEO @NelloMainolfi on @BiotechTVHQ to discuss our exciting achievements over the past year and how we’re harnessing the power of #TPD to develop differentiated medicines with the potential to address critical health problems and improve patients’ lives.
#ReinventingMedicine $KYMR

[Kymera Therapeutics @KymeraTx]

Our Head of Research, Juliet Williams, was featured today in @DrugTargetRev's #WomenInSTEM series! She reflects on her career leading highly productive scientific teams in novel #drugdiscovery research and shares key learnings and advice for women looking to pursue careers in #STEM. Read the full article here: https://t.co/7HqQVowMO9
#Pioneer #ReinventingMedicine

[Boston Business Journal @BosBizJournal]

When Kymera Therapeutics signed the lease at Arsenal on the Charles, there wasn't even a building yet, so they were able to design the space with an architect. Check out photos of its new lab and office space. https://t.co/XY45CG5Oe0

[Kymera Therapeutics @KymeraTx]

We're thrilled that our first-in-class oral IRAK4 degrader, KT-474, the first clinical heterobifunctional degrader in #immunology, has been nominated as a finalist for Molecule of the Year by @drughuntersite! Don't forget to vote! https://t.co/9xoiBC6cnY
#TPD #DrugDiscovery

[Kymera Therapeutics @KymeraTx]

Today at our R&D Day, we're excited to share an overview of our strategy to build an industry leading #immunology pipeline of oral degrader medicines with the potential to transform treatment paradigms. And we're thrilled to unveil two first-in-class programs targeting STAT6 and TYK2, essential signaling nodes in genetically and clinically validated pathways in diseases that are undrugged or inadequately drugged by other technologies. Learn more about how we're leveraging our disease agnostic #TPD platform to revolutionize the treatment of complex immuno-inflammatory diseases: https://t.co/Gzmv0ep8zk

You can listen to the live webcast of our virtual R&D Day presentations here: https://t.co/DSP4VDyTEi

[Kymera Therapeutics @KymeraTx]

We're honored to share that Kymera has been recognized as a #TopPlacetoWork in Massachusetts by the @BostonGlobe for the second year in a row! Our shared values and deep commitment to helping patients are the foundation of our culture and connect us to Kymera’s mission. Hear from a few of our team members!  
#workboston #Pioneer #Collaborate #Belong

[Kymera Therapeutics @KymeraTx]

Today we shared our second quarter 2023 financial results, as well as recent company updates and upcoming milestones. Learn more about the progress we’ve made on our ambitious plans to build a best-in-class, fully integrated global medicines company here: https://t.co/kQVMt5KumV